Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 9-month Business Results
November 24, 2003
- MEDICAL DEVICE NEWS IN BRIEF
November 24, 2003
- Toyama Chemical: Business Hit by Delay in TTP's Marketing Activities
November 24, 2003
- DIAGNOSTIC NEWS IN BRIEF
November 24, 2003
- Taisho: Synergistic Effect of Integration Not Yet Seen
November 24, 2003
- OTC NEWS IN BRIE
November 24, 2003
- Santen: Overall Sales Down Slightly from Sluggish Domestic Sales
November 24, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 24, 2003
- Ono: Sales Increase 2.8%, Profits Up 3.9%
November 24, 2003
- Statement on Proper Use of Iressa Issued by JLCS
November 24, 2003
- Dainippon: Rapid Drop in Sales of Gatiflo Hurts Sales, Profits
November 24, 2003
- Micardis Exerts Hypotensive Effects for 24-hour: JSH Meeting
November 24, 2003
- Tanabe Seiyaku: 9.7% Increase in Net Profits Despite Sales Drop
November 24, 2003
- Home Blood Pressure GL Compiled by JSH
November 24, 2003
- SEMIANNUAL BUSINESS RESULTS
November 17, 2003
- BUSINESS NEWS IN BRIEF
November 17, 2003
- Press Seminar
November 17, 2003
- Industry Polarization Became Marked in the Last Decade
November 17, 2003
- MEDICAL DEVICE NEWS IN BRIEF
November 17, 2003
- Taiyo Pharmaceutical: Sales Up 46.0%, Ordinary Profits Up 86.0%
November 17, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…